Browse by author
Lookup NU author(s): Professor Andy HusbandORCiD, Dr Katy Hester, Professor Anthony De SoyzaORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© The Author(s), 2024. Non-cystic fibrosis bronchiectasis is a long-term lung disease characterised by abnormal dilatation of the bronchi, with patients experiencing chronic productive cough and recurrent exacerbations. Currently, there are no licensed drugs for use in bronchiectasis while clinical trials have been conducted to either test new drugs or repurpose existing ones. These drugs target the underlying pathophysiology of bronchiectasis which is known to include infection, inflammation, mucus hypersecretion and retention. Most of the drugs used in daily clinical practice for bronchiectasis are off-label with no randomised trials exploring their safety. This review aims at exploring the safety profile of drugs frequently used in clinical practice to manage bronchiectasis, including antibiotics (e.g. macrolides, aminoglycosides, polymyxins, fluoroquinolones, aztreonam), mucoactive therapy (e.g. hypertonic saline, mannitol, DNase and carbocisteine), anti-inflammatory therapy (inhaled corticosteroids) and drugs currently in development for use in bronchiectasis (e.g. brensocatib, benralizumab and itepekimab).
Author(s): Upadhyay H, Aliberti S, Husband A, Chalmers JD, Hester K, De Soyza A
Publication type: Review
Publication status: Published
Journal: Therapeutic Advances in Drug Safety
Year: 2024
Volume: 15
Pages: 1-18
Online publication date: 30/09/2024
Acceptance date: 08/08/2024
ISSN (print): 2042-0986
ISSN (electronic): 2042-0994
Publisher: SAGE Publications Ltd
URL: https://doi.org/10.1177/20420986241279213
DOI: 10.1177/20420986241279213
Data Access Statement: Availability of data and materials not applicable as this is a review article based on existing literature
